Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

Right arrow Help viewing high resolution images
Right arrow Return to article

Please click here to obtain permission to reproduce this image.

Click on image to view larger version.


Figure 3


Figure 3 PPAR{alpha} Is Required for Pioglitazone-Mediated Repression of TNF{alpha}-Induced Endothelial VCAM-1 mRNA Expression

Northern blot analysis was performed on total RNA isolated from PPAR{alpha}–/– endothelial cells transfected either with PPAR{alpha}-containing pSG5 overexpression vector (A) or pSG5 alone (B) before stimulation with TNF{alpha} in either the absence or presence of WY (100 µM) or pioglitazone (10 µM), with subsequent probing for VCAM-1 or GAPDH expression. (C) Quantification of the VCAM-1 mRNA response to pioglitazone relative to GAPDH mRNA expression levels (n = 3, #p < 0.05 TNF{alpha} vs. vehicle; *p < 0.05 pioglitazone/TNF{alpha} vs. TNF{alpha} alone; {dagger}p < 0.05 WY14643/TNF{alpha} vs. TNF{alpha} alone, Mann-Whitney U test). (D) Cells were transfected in panels A and B but with a concentration gradient of pSG5-PPAR{alpha} as shown before TNF{alpha} stimulation in either the absence or presence of pioglitazone 10 µM (n = 3, *p < 0.05 pioglitazone/TNF{alpha} vs. TNF{alpha} alone). Abbreviations as in Figure 1.





Right arrow Return to article

 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement